The session dedicated to acne will have outstanding presentations on the role of the microbiome in the modulations of acne, as well as the spectrum of severe forms of acne. The session dedicated to hidradenitis suppurativa will focus on pathophysiology, managing comorbidities and treatment.

The “What is New in Paediatric Dermatology” session will focus on the latest updates in autoinflammatory disorders, genetics, biologics and allergic contact dermatitis in children. This comprehensive overview will take a closer look at the latter two areas, providing valuable insights into the latest research and cutting-edge treatment options available

Keratinocytic skin cancers are the most common type of cancer in the world. According to estimates, 3.7-4% of SCCs metastasize and 3-4.6% recur locally. Metastasis is extremely rare in BCC, with local relapse occurring in 2-8% of patients.

The “interactive clinical cases” sessions provide dermatologists’ observations for differential diagnosis and disease management in their daily practices.

The session dedicated to what’s new in allergology and drug eruptions will focus on new contact allergens,
adverse events of new cancer therapies, treatment perspectives in severe drug reactions and new treatments for chronic urticaria.

Psoriasis has been a key driver of modern dermatology over the past 2 decades, owing to the discovery of pathogenic immune events and the development of highly-effective targeted therapies.